Tumor-infiltrating lymphocytes predict cutaneous melanoma survival

Melanoma Research

Volumn 25, Issue 4, 2015, Pages 306-311

  Fortes, Cristina ^a   Mastroeni, Simona ^a   Mannooranparampil, Thomas J ^a   Passarelli, Francesca ^b   Zappalà, Alba ^c   Annessi, Giorgio ^b   Marino, Claudia ^e   Caggiati, Alessio ^d   Russo, Nicoletta ^a   Michelozzi, Paola ^e  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b San Marco Clinic   (Italy)

^c Oncology Unit   (Italy)

^d Surgery Department of Plastic Surgery   (Italy)

^e IDI IRCCS ^*  (Italy)

Author keywords

melanoma; mortality; survival; tumor infiltrating lymphocytes

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BRESLOW THICKNESS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CUTANEOUS MELANOMA; DISEASE SEVERITY ASSESSMENT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MITOSIS RATE; PRIORITY JOURNAL; RISK REDUCTION; SEX DIFFERENCE; SKIN ULCER; SURVIVAL RATE; SURVIVAL TIME; TUMOR ASSOCIATED LEUKOCYTE; VERY ELDERLY; IMMUNOLOGY; LYMPH NODE METASTASIS; MELANOMA; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SENTINEL LYMPH NODE BIOPSY; SKIN TUMOR; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 84936948533     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000164     Document Type: Article

References (23)

1. American Cancer Society. Available at: http://www.cancer.org/cancer/skincancermelanoma/detailedguide/melanoma-skin-cancer-keystatistics. [Accessed 28 November 2014].
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49:1374-1403.
3. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199-6206.
4. McGovern VJ, Shaw HM, Milton GW. Prognosis in patients with thin malignant melanoma: influence of regression. Histopathology 1983; 7:673-680.
5. Fortes C, Mastroeni S, Sera F, Concolino F, Abeni D, Melchi F, et al. Survival and prognostic variables of cutaneous melanoma observed between 1995 and 2000 at Istituto Dermopatico Dell'Immacolata (IDI-IRCCS), Rome, Italy. Eur J Cancer Prev 2006; 15:171-177.
6. Sahin S, Rao B, Kopf AW, Lee E, Rigel DS, Nossa R, et al. Predicting tenyear survival of patients with primary cutaneous melanoma: corroboration of a prognostic model. Cancer 1997; 80:1426-1431.
7. Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol 2012; 30:2678-2683.
8. Barnhill RL, Fine JA, Roush GC, Berwick M. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 1996; 78:427-432.
9. Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol 2007; 25:869-875.
10. Burton AL, Roach BA, Mays MP, Chen AF, Ginter BA, Vierling AM, et al. Prognostic significance of tumor infiltrating lymphocytes in melanoma. Am Surg 2011; 77:188-192.
11. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77:1303-1310.
12. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172:902-908.
13. Barnhill RL. Pathology of melanocytic nevi and malignant melanoma. Boston, UK: Butterworth-Heinemann; 1995.
14. Caggiati A, Migliano E, Potenza C, Gabrielli F, Tartaglione G, Pacchiarotti A, et al. Sentinel node biopsy for malignant melanoma. Technical details and clinical results on 390 patients. Minerva Chir 2002; 57:481-487.
15. Clark WH Jr, Elder DE, Guerry D 4th, Braitman LE, Trock BJ, Schultz D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989; 81:1893-1904.
16. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410:1107-1111.
17. Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev 2014; 257:56-71.
18. Coulie PG, van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 2014; 14:135-146.
19. Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002; 188:51-64.
20. Moore OS Jr, Foote FW Jr. The relatively favorable prognosis of medullary carcinoma of the breast. Cancer 1949; 2:635-642.
21. Day CL Jr, Lew RA, Mihm MC Jr, Harris MN, Kopf AW, Sober AJ, Fitzpatrick TB. The natural break points for primary-tumor thickness in clinical Stage I melanoma. N Engl J Med 1981; 305:1155.
22. Rao UN, Lee SJ, Luo W, Mihm MC Jr, Kirkwood JM. Presence of tumorinfiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials. Am J Clin Pathol 2010; 133:646-653.
23. Balermpas P, Michel Y, Wagenblast J, Seitz O, Weiss C, Rödel F, et al. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br J Cancer 2014; 110:501-509.